• A story in the Aug. 28, 2003, issue of BioWorld Today should have said TolerRx Inc.'s technology is intended to modify antibodies to induce immunological tolerance to themselves.

A news brief in the Aug. 27, 2003, issue of BioWorld Today regarding Amgen Inc.'s Aranesp SingleJect product should have said Aranesp was first approved in September 2001 for chronic renal failure.

Editor's note: The correction will be made on BioWorld Online.